PDS Financial Statements From 2010 to 2025

PDSB Stock  USD 1.24  0.05  4.20%   
PDS Biotechnology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing PDS Biotechnology's valuation are provided below:
PDS Biotechnology Corp does not now have any trending fundamental ratios for analysis.
Check PDS Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PDS Biotechnology's main balance sheet or income statement drivers, such as , as well as many indicators such as . PDS financial statements analysis is a perfect complement when working with PDS Biotechnology Valuation or Volatility modules.
Check out the analysis of PDS Biotechnology Correlation against competitors.

PDS Biotechnology Corp Company Return On Equity Analysis

PDS Biotechnology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current PDS Biotechnology Return On Equity

    
  -1.19  
Most of PDS Biotechnology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PDS Biotechnology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, PDS Biotechnology Corp has a Return On Equity of -1.1922. This is 95.03% lower than that of the Biotechnology sector and 96.73% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

PDS Biotechnology Corp Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining PDS Biotechnology's current stock value. Our valuation model uses many indicators to compare PDS Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PDS Biotechnology competition to find correlations between indicators driving PDS Biotechnology's intrinsic value. More Info.
PDS Biotechnology Corp is regarded fifth in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PDS Biotechnology's earnings, one of the primary drivers of an investment's value.

About PDS Biotechnology Financial Statements

PDS Biotechnology stakeholders use historical fundamental indicators, such as PDS Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although PDS Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in PDS Biotechnology's assets and liabilities are reflected in the revenues and expenses on PDS Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PDS Biotechnology Corp. Please read more on our technical analysis and fundamental analysis pages.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey. Pds Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:
Check out the analysis of PDS Biotechnology Correlation against competitors.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.